MX2020012373A - Vacuna de peptido inverso. - Google Patents

Vacuna de peptido inverso.

Info

Publication number
MX2020012373A
MX2020012373A MX2020012373A MX2020012373A MX2020012373A MX 2020012373 A MX2020012373 A MX 2020012373A MX 2020012373 A MX2020012373 A MX 2020012373A MX 2020012373 A MX2020012373 A MX 2020012373A MX 2020012373 A MX2020012373 A MX 2020012373A
Authority
MX
Mexico
Prior art keywords
peptide vaccine
reverse peptide
encoded
compositions
orf
Prior art date
Application number
MX2020012373A
Other languages
English (en)
Inventor
Ramila Philip
Dr Richard David Perrins
Xiaofang Huang
Thomas Rademacher
Christopher Upton
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of MX2020012373A publication Critical patent/MX2020012373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a composiciones vacunales que comprenden péptidos codificados por un marco abierto de lectura (ORF) codificado por al menos parte del genoma de un virus de ARNmc en sentido opuesto al ARN de sentido positivo capaz de traducirse, y al uso de dichas composiciones para el tratamiento y la prevención de infecciones víricas.
MX2020012373A 2018-05-18 2019-05-20 Vacuna de peptido inverso. MX2020012373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862673647P 2018-05-18 2018-05-18
PCT/GB2019/051386 WO2019220150A1 (en) 2018-05-18 2019-05-20 Reverse peptide vaccine

Publications (1)

Publication Number Publication Date
MX2020012373A true MX2020012373A (es) 2021-02-09

Family

ID=66641168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012373A MX2020012373A (es) 2018-05-18 2019-05-20 Vacuna de peptido inverso.

Country Status (12)

Country Link
US (1) US20210299241A1 (es)
EP (1) EP3793593A1 (es)
CN (1) CN112654364A (es)
AU (1) AU2019270582A1 (es)
BR (1) BR112020023354A2 (es)
CA (1) CA3099643A1 (es)
EA (1) EA202092447A1 (es)
IL (1) IL278830A (es)
MX (1) MX2020012373A (es)
PH (1) PH12020551944A1 (es)
SG (1) SG11202011122XA (es)
WO (1) WO2019220150A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008250D0 (en) * 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
WO2022175330A1 (en) * 2021-02-16 2022-08-25 Emergex Vaccines Holding Limited Reverse peptides from coronavirus for immunogenic purposes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9202968L (sv) * 1992-10-09 1994-04-10 Replico Medical Ab Nya peptider, diagnostiska antigener, deras användning, vacciner och medikamenter
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
ES2625905T3 (es) 2004-10-01 2017-07-20 Midatech Ltd. Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores
EP1919507A2 (en) 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
US9119810B2 (en) * 2005-11-18 2015-09-01 Rutgers, The State University Of New Jersey Compositions and vaccines against influenza A and influenza B infections
CN1810961B (zh) * 2006-02-22 2010-05-12 中国人民解放军军事医学科学院微生物流行病研究所 一种重组流感病毒及其制备方法与应用
ATE517613T1 (de) 2006-04-13 2011-08-15 Midatech Ltd Nanoteilchen mit drei verschiedenen liganden zur auslösung einer immunantwort gegen infektiöse mittel
US20120294879A1 (en) * 2009-10-13 2012-11-22 National University Of Singapore Consensus sequence for influenza a virus
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
ES2627507T3 (es) 2011-09-07 2017-07-28 Midatech Ltd. Composiciones de nanopartícula-péptido
WO2018127689A1 (en) * 2017-01-03 2018-07-12 Emergex Vaccines Holdings Ltd Universal influenza vaccine compositions

Also Published As

Publication number Publication date
CN112654364A (zh) 2021-04-13
AU2019270582A1 (en) 2020-11-26
CA3099643A1 (en) 2019-11-21
EP3793593A1 (en) 2021-03-24
PH12020551944A1 (en) 2021-08-16
EA202092447A1 (ru) 2021-04-26
WO2019220150A1 (en) 2019-11-21
US20210299241A1 (en) 2021-09-30
IL278830A (en) 2021-01-31
SG11202011122XA (en) 2020-12-30
BR112020023354A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
MX2024001134A (es) Meganucleasas manipuladas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CA3009928A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
PH12020551944A1 (en) Reverse peptide vaccine
MX2021005345A (es) Composiciones y metodos.
PH12017500450A1 (en) Flavivirus virus like particle
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MY187896A (en) Dengue virus vaccine compositions and methods of use thereof
MX2015010366A (es) Parvovirus porcino 5b, metodos de uso y vacuna.
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
PH12018500468A1 (en) Fusion protein
NZ750578A (en) Viral vaccines
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c